Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)

DRUG2 trials

Sponsors

Universitair Medisch Centrum Groningen, Universitair Medisch Centrum Groningen, Hipra Scientific S.L., Hipra Scientific S.L.

Conditions

COVID-19COVID-19 diseaseHerpes Zosterimpaired immunitykidney transplantation

Phase 2

A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunogenicity of a booster vaccination with an adapted recombinant protein RBD fusion homodimer candidate (PHH-1V81) against SARS-CoV-2, in adults vaccinated against COVID-19.

CompletedCTIS2023-508458-25-00

Hipra Scientific S.L., Hipra Scientific S.L.COVID-19 disease

Start: 2023-11-13End: 2024-06-17Target: 612Updated: 2024-02-08

Phase 3

Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients

CompletedCTIS2023-503894-39-00

Universitair Medisch Centrum Groningen, Universitair Medisch Centrum GroningenCOVID-19, Herpes Zoster, impaired immunity +1

Start: 2023-08-22End: 2024-02-27Target: 110Updated: 2023-10-10